Your browser doesn't support javascript.
loading
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
Docherty, Kieran F; Welsh, Paul; Verma, Subodh; De Boer, Rudolf A; O'Meara, Eileen; Bengtsson, Olof; Køber, Lars; Kosiborod, Mikhail N; Hammarstedt, Ann; Langkilde, Anna Maria; Lindholm, Daniel; Little, Dustin J; Sjöstrand, Mikaela; Martinez, Felipe A; Ponikowski, Piotr; Sabatine, Marc S; Morrow, David A; Schou, Morten; Solomon, Scott D; Sattar, Naveed; Jhund, Pardeep S; McMurray, John J V.
Afiliação
  • Docherty KF; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (K.F.D., P.W., N.S., P.S.J., J.J.V.M.).
  • Welsh P; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (K.F.D., P.W., N.S., P.S.J., J.J.V.M.).
  • Verma S; Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Canada (S.V.).
  • De Boer RA; Department of Cardiology, University Medical Center and University of Groningen, The Netherlands (R.A.D.B.).
  • O'Meara E; Montreal Heart Institute, Université de Montréal, Canada (E.O.).
  • Bengtsson O; AstraZeneca R&D, Gothenburg, Sweden (O.B., A.H., A.M.L., D.L., D.J.L., M. Sjöstrand).
  • Køber L; Rigshospitalet Copenhagen University Hospital, Denmark (L.K.).
  • Kosiborod MN; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.N.K.).
  • Hammarstedt A; George Institute for Global Health, University of New South Wales, Sydney, Australia (M.N.K.).
  • Langkilde AM; AstraZeneca R&D, Gothenburg, Sweden (O.B., A.H., A.M.L., D.L., D.J.L., M. Sjöstrand).
  • Lindholm D; AstraZeneca R&D, Gothenburg, Sweden (O.B., A.H., A.M.L., D.L., D.J.L., M. Sjöstrand).
  • Little DJ; AstraZeneca R&D, Gothenburg, Sweden (O.B., A.H., A.M.L., D.L., D.J.L., M. Sjöstrand).
  • Sjöstrand M; AstraZeneca R&D, Gothenburg, Sweden (O.B., A.H., A.M.L., D.L., D.J.L., M. Sjöstrand).
  • Martinez FA; AstraZeneca R&D, Gothenburg, Sweden (O.B., A.H., A.M.L., D.L., D.J.L., M. Sjöstrand).
  • Ponikowski P; George Institute for Global Health, University of New South Wales, Sydney, Australia (M.N.K.).
  • Sabatine MS; Wroclaw Medical University, Poland (P.P.).
  • Morrow DA; TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA (M.S.S., D.A.M.).
  • Schou M; TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA (M.S.S., D.A.M.).
  • Solomon SD; Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M. Schou).
  • Sattar N; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (S.D.S.).
  • Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (K.F.D., P.W., N.S., P.S.J., J.J.V.M.).
  • McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (K.F.D., P.W., N.S., P.S.J., J.J.V.M.).
Circulation ; 146(13): 980-994, 2022 09 27.
Article em En | MEDLINE | ID: mdl-35971840
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Deficiências de Ferro / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Deficiências de Ferro / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article